Logo image of POAI

PREDICTIVE ONCOLOGY INC (POAI) Stock Fundamental Analysis

USA - NASDAQ:POAI - US74039M3097 - Common Stock

14.5 USD
+0.24 (+1.68%)
Last: 10/8/2025, 8:08:56 PM
Fundamental Rating

1

POAI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of POAI have multiple concerns. POAI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

POAI had negative earnings in the past year.
In the past year POAI has reported a negative cash flow from operations.
POAI had negative earnings in each of the past 5 years.
POAI had a negative operating cash flow in each of the past 5 years.
POAI Yearly Net Income VS EBIT VS OCF VS FCFPOAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -284.62%, POAI is not doing good in the industry: 95.29% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -284.62%
ROE N/A
ROIC N/A
ROA(3y)-150.57%
ROA(5y)-139.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
POAI Yearly ROA, ROE, ROICPOAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K -5K -10K -15K -20K

1.3 Margins

POAI has a Gross Margin of 48.54%. This is comparable to the rest of the industry: POAI outperforms 43.46% of its industry peers.
POAI's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for POAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.14%
GM growth 5Y-4.67%
POAI Yearly Profit, Operating, Gross MarginsPOAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

0

2. Health

2.1 Basic Checks

POAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, POAI has more shares outstanding
The number of shares outstanding for POAI has been increased compared to 5 years ago.
There is no outstanding debt for POAI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
POAI Yearly Shares OutstandingPOAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
POAI Yearly Total Debt VS Total AssetsPOAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -83.71, we must say that POAI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -83.71, POAI is doing worse than 95.29% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -83.71
ROIC/WACCN/A
WACC8.8%
POAI Yearly LT Debt VS Equity VS FCFPOAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 0.32 indicates that POAI may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.32, POAI is doing worse than 94.24% of the companies in the same industry.
A Quick Ratio of 0.31 indicates that POAI may have some problems paying its short term obligations.
The Quick ratio of POAI (0.31) is worse than 93.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.32
Quick Ratio 0.31
POAI Yearly Current Assets VS Current LiabilitesPOAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

5

3. Growth

3.1 Past

POAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.02%, which is quite impressive.
Looking at the last year, POAI shows a very negative growth in Revenue. The Revenue has decreased by -38.96% in the last year.
The Revenue has been growing slightly by 2.86% on average over the past years.
EPS 1Y (TTM)59.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.73%
Revenue 1Y (TTM)-38.96%
Revenue growth 3Y4.57%
Revenue growth 5Y2.86%
Sales Q2Q%-99.03%

3.2 Future

POAI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.66% yearly.
POAI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 158.10% yearly.
EPS Next Y93.75%
EPS Next 2Y42.77%
EPS Next 3Y28.66%
EPS Next 5YN/A
Revenue Next Year569.48%
Revenue Next 2Y232.87%
Revenue Next 3Y158.1%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
POAI Yearly Revenue VS EstimatesPOAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
POAI Yearly EPS VS EstimatesPOAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

POAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 177.70, the valuation of POAI can be described as expensive.
Based on the Price/Forward Earnings ratio, POAI is valued a bit cheaper than the industry average as 66.49% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.30. POAI is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 177.7
POAI Price Earnings VS Forward Price EarningsPOAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
POAI Per share dataPOAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates POAI does not grow enough to justify the current Price/Earnings ratio.
POAI's earnings are expected to grow with 28.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.77%
EPS Next 3Y28.66%

More info and screens

0

5. Dividend

5.1 Amount

POAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PREDICTIVE ONCOLOGY INC

NASDAQ:POAI (10/8/2025, 8:08:56 PM)

14.5

+0.24 (+1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12
Earnings (Next)11-10 2025-11-10
Inst Owners1.59%
Inst Owner Change0%
Ins Owners6.32%
Ins Owner Change19.64%
Market Cap11.02M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-96.31%
Min Revenue beat(2)-99.82%
Max Revenue beat(2)-92.79%
Revenue beat(4)1
Avg Revenue beat(4)-38.34%
Min Revenue beat(4)-99.82%
Max Revenue beat(4)71.43%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 177.7
P/S 10.3
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-20.64
EYN/A
EPS(NY)0.08
Fwd EY0.56%
FCF(TTM)-12.37
FCFYN/A
OCF(TTM)-12.37
OCFYN/A
SpS1.41
BVpS-2.18
TBVpS-2.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -284.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.54%
FCFM N/A
ROA(3y)-150.57%
ROA(5y)-139.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.14%
GM growth 5Y-4.67%
F-Score3
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.32
Quick Ratio 0.31
Altman-Z -83.71
F-Score3
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)20.65%
Cap/Depr(5y)33.78%
Cap/Sales(3y)11.77%
Cap/Sales(5y)26.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.73%
EPS Next Y93.75%
EPS Next 2Y42.77%
EPS Next 3Y28.66%
EPS Next 5YN/A
Revenue 1Y (TTM)-38.96%
Revenue growth 3Y4.57%
Revenue growth 5Y2.86%
Sales Q2Q%-99.03%
Revenue Next Year569.48%
Revenue Next 2Y232.87%
Revenue Next 3Y158.1%
Revenue Next 5YN/A
EBIT growth 1Y33.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.34%
OCF growth 3YN/A
OCF growth 5YN/A